Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors, and Breast Cancer in particular.

Presentation topics will include:

• Latest data in Breast Cancer from 2020 publications and abstracts
• Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection
• Signatera clinical data in early and late stage Breast Cancer
• Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout